TLC and Strides Enter Agreement for AmphoTLC™ in IndiaLicense Supply and Commercialization Agreement • May 27th, 2021
Contract Type FiledMay 27th, 202127, 2021 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Strides Pharma Science Limited (Strides, BSE: 532531, NSE: STAR), a global pharmaceutical company, have entered a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.